|
Research Management and Support
|
RMS ES 2016
|
$320,501,735
|
$20,000
|
N/A
|
National Institutes of Health
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-08
|
$462,791
|
$462,791
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Defining mechanisms of cancer chemoresistance and metastasis
|
5R00CA172697-04
|
$246,504
|
$246,504
|
ACHARYYA, SWARNALI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Center for Multiple Myeloma Nanotherapy
|
3U54CA199092-01S1
|
$27,659
|
$19,638
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Center for Multiple Myeloma Nanotherapy
|
3U54CA199092-02S1
|
$57,523
|
$40,841
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
WU-MDACC Inter-Institutional Molecular Imaging Center
|
4P50CA094056-16
|
$1,286,033
|
$77,162
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-02
|
$2,230,648
|
$1,583,760
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Phase 2 Clinical Trials Program for Experimental Therapeutics Clinical Trials Network
|
3UM1CA186686-03S1
|
$912,510
|
$912,510
|
ADJEI, ALEX
|
MAYO CLINIC ROCHESTER
|
|
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis
|
5UM1CA186686-03
|
$718,215
|
$718,215
|
ADJEI, ALEX
|
MAYO CLINIC ROCHESTER
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
1R44CA203336-01
|
$299,985
|
$299,985
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-09S1
|
$156,773
|
$18,813
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
4U54CA137788-09
|
$1,241,114
|
$148,934
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction
|
4R01CA172741-04
|
$279,793
|
$279,793
|
AJANI, JAFFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Immuno/Immuno-Gene Therapies for Thoracic Malignancies
|
4P01CA066726-19
|
$1,182,811
|
$224,734
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer
|
4R01CA172921-04
|
$357,673
|
$178,837
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-08S1
|
$244,135
|
$2,441
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-08S2
|
$124,997
|
$1,250
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-08S3
|
$109,572
|
$1,096
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-08S4
|
$104,650
|
$1,047
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
5P30CA138313-08
|
$2,093,000
|
$20,930
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-03
|
$435,560
|
$143,735
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
Therapeutic resistance in leukemic cells: targeting BCL-2 family and autophagy
|
5R01CA184137-02
|
$362,569
|
$362,569
|
ALMASAN, ALEXANDRU
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics
|
5U01CA202144-02
|
$590,758
|
$590,758
|
ALTER, ORLY
|
UNIVERSITY OF UTAH
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-47S1
|
$142,498
|
$4,275
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-47
|
$2,645,581
|
$79,367
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Novel Markers for Disease Outcome in Breast Cancer
|
ZIA BC 010887
|
$488,242
|
$97,648
|
Ambs, Stefan
|
CCR (NCI)
|
|
The development of radiolabeled probes for imaging and therapy which target the chemokine CXCR4
|
1F32CA203473-01
|
$56,118
|
$28,059
|
AMOR-COARASA, ALEJANDRO
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy
|
5R01CA182872-03
|
$628,483
|
$628,483
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
SPORE in Multple Myeloma
|
4P50CA100707-14
|
$2,162,000
|
$1,297,200
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Sensitization to CD47 Blockade to Enhance Anti-Tumor Immunity
|
5F30CA195973-02
|
$42,446
|
$42,446
|
ANDERSON, KATIE
|
UNIVERSITY OF MINNESOTA
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
5R01CA050947-24
|
$301,545
|
$150,773
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Clinical trials in women's cancers
|
ZIA BC 011584
|
$163,658
|
$81,829
|
Annunziata, Christina
|
CCR (NCI)
|
|
Targeting the MET pathway in urothelial carcinoma
|
ZIA BC 011594
|
$539,065
|
$242,579
|
Apolo, Andrea
|
CCR (NCI)
|
|
Longitudinal Cardiotoxicity in Adult Survivors Childhood Cancer
|
4R01CA157838-05
|
$536,801
|
$536,801
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Childhood Cancer Survivor Study
|
4U24CA055727-22
|
$4,172,004
|
$1,668,802
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Targeting to Epigenetic Modications in ALL
|
7R01CA176745-06
|
$402,250
|
$402,250
|
ARMSTRONG, SCOTT
|
DANA-FARBER CANCER INST
|
|
SPORE in Breast Cancer
|
3P50CA098131-15S1
|
$750,000
|
$187,500
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
SPORE in Breast Cancer
|
5P50CA098131-15
|
$2,162,000
|
$540,500
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Cancer Center Support Grant
|
3P30CA082103-18S1
|
$121,856
|
$8,530
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S2
|
$155,534
|
$10,887
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S3
|
$60,000
|
$4,200
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S4
|
$80,100
|
$5,607
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S5
|
$200,000
|
$14,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S6
|
$152,100
|
$10,647
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S7
|
$200,000
|
$14,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S8
|
$749,207
|
$52,444
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
4P30CA082103-18
|
$7,063,742
|
$494,462
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
A Prospective Study of the Impact of Breast Cancer on Symptoms and Functioning
|
5R01CA199137-02
|
$524,557
|
$173,104
|
AVIS, NANCY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
PET Kinetic Modeling of Inhibiting Glycolysis in Ovarian Cancer
|
5R21CA198795-02
|
$222,296
|
$222,296
|
AVRIL, NORBERT
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Using FAP to Selectively Target Epithelial Cancers
|
4R01CA163930-05
|
$349,435
|
$174,718
|
BACHOVCHIN, WILLIAM
|
TUFTS UNIVERSITY BOSTON
|
Total relevant funding to Chemotherapy for this search: $289,467,872
|